blog.aids.gov − NIAID
AIDS.GOV | SERVICE LOCATOR | SEARCH

BLOG.AIDS.GOV - Changing to HIV.gov in Spring 2017

MENU

NIAID

Prevention Studies In 2016 Set the Stage for Progress

It is fitting that in the year that we marked the 35th anniversary of the first recognition of what would come to be known as HIV, we’ve taken major steps toward revolutionizing how we could prevent this disease. In 2016 we began four important clinical studies that promise to inform HIV prevention research, which may…

Historic HIV Vaccine Clinical Trial: Facebook Live with NIH’s Dr. Dieffenbach

In a Facebook Live interview from Cape Town, South Africa earlier this week, we heard from NIH’s Dr. Carl Dieffenbach about the exciting launch of HVTN 702, a new HIV vaccine clinical trial supported by NIH. The first HIV vaccine efficacy study to launch anywhere in seven years, HVTN 702 is testing whether an experimental…

NIH Statement on World AIDS Day 2016

This year, the world marked the 35th anniversary of the first published reports of what would come to be known as HIV/AIDS. This disease has wrought enormous suffering and devastation and caused more than 35 million deaths. Yet today, thanks to remarkable achievements in biomedical science and public health, we have the tools to build…

Watch HIV Vaccine Trial Launch in South Africa Via Facebook Live! This Wednesday!

Director’s Note, Office of HIV/AIDS and Infectious Disease Policy, HHS: Scientific advances have given us the tools we need to end new HIV infections and save lives. But our work is not yet done, either here in the U.S. or around the world. As we approach the observance of World AIDS Day on December 1…

NIH Spotlights HIV Cure Research

In two Facebook Live events from NIAID’s Strategies for an HIV Cure conference this week we learned about advances in HIV cure research from leaders in HIV science. Dr. Fauci Reflects on the State of HIV Cure Research As the third biennial conference got underway on the NIH campus in Bethesda, Maryland, we had the…

NIH’s Dr. Carl Dieffenbach Discusses Viral Suppression

Dr. Carl Dieffenbach, Director of the Division of AIDS at NIH’s National Institute of Allergy and Infectious Diseases (NIAID), has spoken with AIDS.gov about the important issue of viral suppression at several major HIV conferences during the past few months, including the HIV Research for Prevention (R4P) Conference in Chicago, the 2016 Ryan White Conference in Washington, DC,…

ICYMI – Advances in Research on HIV Prevention for Women

Last week, in a Facebook Live event we heard from NIH’s Dr. Carl Dieffenbach about some new developments in HIV prevention for women shared at the HIV Research for Prevention Conference  (R4P) in Chicago.  Carl is the Director of the Division of AIDS at NIH’s National Institute of Allergy and Infectious Diseases. He and his…

Large Increases in HIV Suppression Needed to Reduce New Infections in Critical Population

NIH-Funded Study Aims to Identify and Treat HIV-Infected Men Who Have Sex With Men Achieving moderate reduction of new HIV infections among men who have sex with men (MSM) will depend on significantly increasing the percentage of HIV-infected MSM whose viral load is suppressed to undetectable levels, according to a new mathematical model based on…